98%
921
2 minutes
20
Understanding early events of HIV transmission within mucosal tissues is vital for developing effective prevention strategies. Here, we report that primary stromal fibroblasts isolated from endometrium, cervix, foreskin, male urethra, and intestines significantly increase HIV infection of CD4+ T cells-by up to 37-fold for R5-tropic HIV and 100-fold for X4-tropic HIV-without themselves becoming infected. Fibroblasts were more efficient than dendritic cells at trans-infection and mediate this response in the absence of the DC-SIGN and Siglec-1 receptors. In comparison, mucosal epithelial cells secrete antivirals and inhibit HIV infection. These data suggest that breaches in the epithelium allow external or luminal HIV to escape an antiviral environment to access the infection-favorable environment of the stromal fibroblasts, and suggest that resident fibroblasts have a central, but previously unrecognized, role in HIV acquisition at mucosal sites. Inhibiting fibroblast-mediated enhancement of HIV infection should be considered as a novel prevention strategy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312882 | PMC |
http://dx.doi.org/10.1371/journal.ppat.1006163 | DOI Listing |
Br J Cancer
September 2025
Division of Cancer Sciences, School of Medical Sciences, University of Leicester, Leicester, UK.
The incidence of oral cavity cancers in the UK is rising. Asian/Asian British ethnic groups and socioeconomically deprived groups are at highest risk with some evidence of worse disease outcomes in South Asian individuals receiving radiotherapy. This variation in incidence and outcomes underscores the urgent need for action.
View Article and Find Full Text PDFTrends Immunol
September 2025
Department of Life Science, University of Seoul, Seoul, Republic of Korea. Electronic address:
Despite an effective combination of antiretroviral therapy, HIV persists as a lifelong infection and global health threat. The human host equips restriction factors and interferon (IFN)-stimulated genes that target every step of the viral life cycle. However, HIV-1 has evolved a coordinated immune evasion strategy using a limited set of accessory proteins with distinct antagonistic functions.
View Article and Find Full Text PDFBMJ Open
September 2025
Public Health Ontario, Toronto, Ontario, Canada
Objectives: Canadian guidelines recommend HIV testing for individuals being evaluated for syphilis. Our objective was to examine three aspects of HIV testing (ie, if an HIV test occurred, the timing of the HIV test in relation to the syphilis test and the proportion with a positive HIV test result) among syphilis tests between 2017 and 2022 from individuals with no evidence of a previous HIV diagnosis.
Design And Setting: This study is a retrospective analysis of comprehensive laboratory testing data from Ontario's provincial public health laboratory.
Gastroenterol Hepatol
September 2025
Inflammatory Bowel Disease Unit, Gastroenterology Department, Institut de Recerca Sant Pau (IR-SantPau), Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain.
Objective: Chlamydia trachomatis is a prevalent cause of infectious proctitis, often misdiagnosed as cancer or inflammatory bowel disease (IBD). This study aims to describe the main clinical symptoms, together with endoscopic and histopathological characteristics of Chlamydia trachomatis proctitis in the general population.
Patients And Methods: A retrospective observational study was conducted at a single institution, identifying all cases of proctitis due to Chlamydia trachomatis infection, detected by real-time PCR in rectal biopsy or anal smear, with endoscopic assessment.
Vaccine
September 2025
Unit of Infectious Diseases, University of Brescia and Spedali Civili Hospital, Brescia, Italy. Electronic address:
Background: People living with HIV (PLWH) have a higher risk of herpes zoster (HZ) reactivation and postherpetic neuralgia (PHN) compared to general population. Our study aims to evaluate prevalence of HZ reactivation and PHN after vaccination with recombinant vaccine (RZV) in a population living with HIV, and to identify risk factors associated with recurrence.
Methods: We conducted an observational study, enrolling all PLWH ≥18 years old vaccinated with RZV from January 2022 to December 2023.